Regenerative Injection for Knee Osteoarthritis in a Patient with Diabetes
A 61-year-old woman with Kellgren-Lawrence grade 3 knee osteoarthritis and type 2 diabetes (HbA1c 8.9%) asks about platelet-rich plasma (PRP) or stem cell injection instead of total knee arthroplasty. She has tried physical therapy, NSAIDs (contraindicated due to CKD stage 3), and corticosteroid injections with short-lived benefit. She has read online claims that regenerative injections "regrow cartilage" and asks whether she can avoid surgery.
1. Counsel her on the evidence and appropriateness of regenerative injections.
Read the worked answer
- Evidence: PRP and other biologics have modest, inconsistent evidence for symptom improvement in knee OA; they are not proven to regrow cartilage or reliably prevent arthroplasty.
- Appropriateness: May be considered as part of a multimodal plan in selected patients, but she should understand limitations, cost, and lack of regulatory standardization.
- Diabetes: Poor glycemic control may affect healing and outcomes; optimize HbA1c first.
Judgment call: Avoid overpromising; present surgery as a reasonable option and support informed choice.
2. What practical and safety considerations apply if she elects to proceed?
Read the worked answer
- Product standardization: Clarify preparation method (leukocyte-rich vs poor), dose, and number of injections; document consent.
- Safety: Sterile technique, infection risk, post-injection flare counseling, and glucose monitoring.
- Follow-up: Define outcome measures and a timeline to reassess; avoid repeated unproven injections without benefit.
Judgment call: Set explicit stopping rules and revisit surgical options if no meaningful improvement.